No evidence for systemic platelet activation during or after orthotopic liver transplantation

Abstract

Platelet function is thought to deteriorate during liver transplantation as a result of platelet activation and proteolysis of platelet receptors by plasmin following reperfusion. However, this hypothesis has never been formally tested. Twenty patients undergoing a first or second liver transplant were included in the study. Blood samples were taken at standardized time points during transplantation and up to 10 days after transplantation. Platelet activation was assessed by detection of the activation markers P-selectin and activated integrin ␣IIb␤3 with flow cytometry. Proteolytic cleavage of platelet receptors was assessed by flow cytometry measurement of the constitutively expressed platelet receptors glycoprotein Ib␣ and integrin ␣IIb␤3. In addition, using enzyme-linked immunosorbent assay techniques, we measured plasma levels of platelet activation products ␤-thromboglobulin and platelet factor 4 and plasma levels of cleaved fragments of glycoproteins Ib␣ and V. Flow cytometry analyses provided no evidence of substantial platelet activation during transplantation. In fact, the expression of activated integrin ␣IIb␤3 decreased postoperatively; this indicated that platelets were in a slightly activated state prior to surgery. Plasma levels of ␤-thromboglobulin and platelet factor 4 also substantially decreased after transplantation. In addition, no changes were observed in the constitutively expressed platelet receptors or in the plasma levels of platelet receptor fragments, and this indicated a lack of substantial receptor proteolysis. In conclusion, no evidence was found for significant activation of circulating blood platelets or the proteolysis of key platelet receptors during liver transplantation. These findings suggest that the platelet functional capacity does not decrease during liver transplantation. Liver Transpl 15:956-962, 2009.

Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient

“…Using a platelet function test in flowing blood, we demonstrated an enhanced capacity of plasma from patients taken during and after OLT to support platelet adhesion, which is likely linked to this profound VWF/ADAMTS13 imbalance . In addition, we have provided evidence that the platelet itself remains functional during and after OLT . Given the thrombotic phenotype associated with isolated ADAMTS13 deficiency or elevated levels of VWF, we hypothesize that the preserved platelet function, in combination with the prothrombotic VWF/ADAMTS13 imbalance results in a normal or even supranormal functional status of the primary haemostatic system.…”

Clinical pig liver xenotransplantation: how far do we have to go?

“…Observations made in patients following liver allotransplantation could possibly provide some insight, as thrombocytopenia has been noted by several groups [22][23][24][25]. Richards et al [22] studied 45 consecutive human patients who underwent liver allotransplantation, of whom 27 experienced a significant reduction in platelet count to <50 000/ mm 3 , with four experiencing counts of <20 000/ mm 3 (Fig.…”

Monitoring and Treatment of Coagulation Disorders in End-Stage Liver Disease

“…The proteins C and S, which are also vitamin K-dependent, are decreased as well [2,4]. In contrast, coagulation factors that are not produced in the liver, such as vWF and factor VIII, show increased serum activity compared to controls [5,6]. One of the main reasons for elevated vWF is their increased release from endothelial cells and a lower serum activity of ADAMTS 13, a metalloprotease enzyme that breaks down the vWF.…”